2020
DOI: 10.1016/j.coi.2020.01.006
|View full text |Cite
|
Sign up to set email alerts
|

DNA vaccines: prime time is now

Abstract: Recently newer synthetic DNA vaccines have been rapidly advanced to clinical study and have demonstrated an impressive degree of immune potency and tolerability. Improvements in DNA delivery over prior needle and syringe approaches include jet delivery, gene gun delivery, among others. Among the most effective of these new delivery methods, advanced electroporation (EP), combined with other advances, induces robust humoral and cellular immunity in both preventative as well as therapeutic studies. Advancements … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
118
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 148 publications
(124 citation statements)
references
References 42 publications
0
118
0
1
Order By: Relevance
“…For these reasons, biologics are gradually becoming the new standard in the medical field. This trend is clearly manifested in the drug market sales worldwide, since many of the most profitable therapeutics available today are biologics such as enzymes, antibodies, peptides, viruses, and nucleic acids [ 33 , 34 , 35 ]. Addressing the many challenges associated with the delivery and release of biologics, including those that are in clinical use, is thus of considerable fundamental and applied interest.…”
Section: Biotechnological Applications Of C3msmentioning
confidence: 99%
See 1 more Smart Citation
“…For these reasons, biologics are gradually becoming the new standard in the medical field. This trend is clearly manifested in the drug market sales worldwide, since many of the most profitable therapeutics available today are biologics such as enzymes, antibodies, peptides, viruses, and nucleic acids [ 33 , 34 , 35 ]. Addressing the many challenges associated with the delivery and release of biologics, including those that are in clinical use, is thus of considerable fundamental and applied interest.…”
Section: Biotechnological Applications Of C3msmentioning
confidence: 99%
“…The number of clinical studies on nucleic acid-based therapies is steadily increasing owing to the versatility and high efficacy of gene therapies with plasmid DNA (pDNA), small interference RNA (siRNA), antisense RNA (mRNA) [ 33 ]. The potency of these high potential treatments can be further improved if the two major bottlenecks of limited physiological stability and inefficient targeting can be tackled successfully.…”
Section: Biotechnological Applications Of C3msmentioning
confidence: 99%
“…To focus Ab responses on the HIV-1 V2 region, we used a vaccination regimen that included priming with DNA encoding a trimeric V1V2 scaffold protein followed by DNA + Protein coimmunization boosts. The use of a nucleic acid-based vaccine is a simple method allowing efficient expression of a structurally defined immunogen which results in the development of both humoral and cellular immunity [reviewed in (34)(35)(36)] that can be maintained for long periods and can be boosted by the same or heterologous boosting strategies (37). This protocol recapitulates our previous experiences in HIV vaccine development: (i) Focusing the immune responses on sub-dominant regions of the HIV proteome which alters the immune response hierarchy by priming with DNA expressing highly conserved regions (CE) of Gag or Env; these responses are greatly augmented by booster vaccination with DNA expressing CE and full-length immunogens (30)(31)(32)(33); (ii) Co-administration of DNA + Protein in the same anatomical sites induces cellular and humoral immune responses of high magnitude and longevity that efficiently disseminate to mucosal sites (21,(38)(39)(40)(41)(42), a strategy corroborated by others (28,(43)(44)(45).…”
Section: Introductionmentioning
confidence: 99%
“…Our results show that priming with V1V2 DNA focuses the Ab responses preferentially on the V2 region, and these V2-specific Abs display potent effector functions, including ADCP and complement activation, features associated to a reduced risk of infection(16)(17)(18)(19)(20)(21)(22)(23)82). These data support the inclusion of V1V2 DNA priming vaccination to increase the magnitude and quality of the V2-specific Ab responses.The use of a nucleic acid-based vaccine is a simple method allowing efficient expression of a structurally defined immunogen, and results in the development of both humoral and cellular immunity [reviewed in(34)(35)(36) which can be maintained for long periods and can be boosted by the same or heterologous boosting strategies(37). The use of DNA for priming immunizations provides a method to focus both Ab and cellular responses, in the absence of immune interference, to any desired protein region(30)(31)(32)(33) resulting in the induction of immune responses with improved recognition of important epitopes associated with protection, as proposed for the V2 epitopes identified by the RV144 trial (2-6).MATERIALS AND METHODSEthics statement.…”
mentioning
confidence: 99%
“…The availability of genome sequences opened up the prospect of the DNA vaccine approach to validate novel vaccine candidates individually or combined to improve vaccine elicitation of cell-mediated and mucosal immunity ( 51 , 52 ). DNA vaccines are simple rings of DNA containing a gene encoding a specific vaccine antigen under the regulation of a promotor ( 53 ).…”
Section: Prospects and Challenges For Anti-sths Vaccine Designmentioning
confidence: 99%